Kate Surdez
Human Resources Officer bei MIMEDX GROUP, INC.
Profil
Kate Surdez is currently the Chief Human Resources Officer at MiMedx Group, Inc. She previously worked as a Global Director at AstraZeneca PLC, Director-Human Resources at Frederick Manufacturing Corp., Senior Vice President & Head-Human Resources at Viela Bio, Inc., and Vice President-People at Vaxxinity, Inc. She obtained an undergraduate degree from The University of North Carolina at Wilmington.
Aktive Positionen von Kate Surdez
| Unternehmen | Position | Beginn |
|---|---|---|
| MIMEDX GROUP, INC. | Human Resources Officer | 18.07.2022 |
Ehemalige bekannte Positionen von Kate Surdez
| Unternehmen | Position | Ende |
|---|---|---|
| VAXXINITY, INC. | Human Resources Officer | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
| Frederick Manufacturing Corp. | Human Resources Officer | - |
| VIELA BIO, INC. | Human Resources Officer | - |
Ausbildung von Kate Surdez
| The University of North Carolina at Wilmington | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| VAXXINITY, INC. | Health Technology |
| MIMEDX GROUP, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Frederick Manufacturing Corp. | Producer Manufacturing |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
